Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

C Dubot,E Bourbouloux,O Mir,Sylvie Kirscher,O Rigal,J M Ferrero,H Cure,Emmanuel Blot,Djelila Allouache,P Cottu,G Romieu,Claudia Lefeuvre,E Malaurie,N Tubianamathieu,Magali Lacroixtriki,F Rollot,H Peyrosaintpaul,C Orsini,F Bonnetain,E Brain

Journal of Geriatric Oncology（2014）

Cited 1|Views54
No score
Abstract
Introduction: The benefit of adjuvant chemotherapy (CT) added to hormonal therapy (HT) compared with HT alone remains debated for women >70 with ER + HER2- breast cancer (BC). Selection of valid indications might be improved by the use of better prognosticator. This trial compares the impact of both strategies on overall survival (OS) according to Genomic Grade (GG).
More
Translated text
Key words
luminal breast carcinoma,adjuvant systemic treatment,genomic prognosticator,elderly women
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined